Unveiling the efficacy and safety of Erenumab, a monoclonal antibody targeting calcitonin gene-related peptide (CGRP) receptor, in patients with chronic and episodic migraine: a GRADE-assessed systematic review and meta-analysis of randomized clinical trials with subgroup analysis

Unveiling the efficacy and safety of Erenumab, a monoclonal antibody targeting calcitonin gene-related peptide (CGRP) receptor, in patients with chronic and episodic migraine: a GRADE-assessed systematic review and meta-analysis of randomized clinical trials with subgroup analysis

Abstract Background Migraine is a highly prevalent and disabling disease, affecting nearly 14% of the global population. Preventive medications involve drugs like beta-adrenergic blockers, antidepressants, and anticonvulsants. However, these drugs lacked effectiveness, and patients showed poor toler...

Full description

Saved in:
Bibliographic Details
Main Authors: Mohamed E. Haseeb, Hazem E. Mohammed, Hatem Yaser, George Hanen, Mohamed Nasser, Shehab Yaser, Zeyad Bady
Format: Article
Language:English
Published: BMC 2025-03-01
Series:Head & Face Medicine
Subjects:
Erenumab
CGRP
Migraine
Efficacy
Safety
Systematic review
Online Access:https://doi.org/10.1186/s13005-025-00494-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13005-025-00494-w

Similar Items